Periprocedural Myocardial Infarction: the Role of Human Neutrophil Peptide-1 to 3

Overview

The aim of this study is to determine the role of human neutrophil peptide-1 to 3 in the occurrence of periprocedural myocardial infarction.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: November 2016

Interventions

  • Other: Blood sample
    • Blood sample drawn from participants for analysis of neutrophil peptide level

Clinical Trial Outcome Measures

Primary Measures

  • Human Neutrophil Peptide Level
    • Time Frame: Two hours
    • Laboratory analysis and measurement of Human Neutrophil Peptide-1 to 3 levels

Participating in This Clinical Trial

Inclusion Criteria

  • Troponin negative patients – Stable angina – Unstable angina – Positive screening tests Exclusion Criteria:

  • Troponin positive – Technical failure of procedure – Hemodynamic unstability

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hillel Yaffe Medical Center
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Rami Abu Fanne, MD, PhD, 972-50-3573694, ramia@hadassah.org.il

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.